Make that 2 approved RNAi drugs at Alnylam after the FDA offers a speedy OK on ultra-rare disease drug
Seventeen years into the game, Alnylam’s pivot into commercial operations is picking up speed.
The bellwether biotech $ALNY has nabbed their second FDA OK for an RNAi drug, this time for givosiran, the only therapy now approved for acute hepatic porphyria. This second approval came months ahead of the February deadline — even after winning priority review following their ‘breakthrough’ title earlier.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 85,300+ biopharma pros reading Endpoints daily — and it's free.